Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Development
Biotech
Merck exec defends aggressive Keytruda prostate cancer program
Three of the four phase 3 prostate cancer programs for Keytruda launched in close succession around 2019 have returned negative.
Angus Liu
Feb 16, 2023 6:30am
Pfizer supports Akero's NASH dreams with $25M investment
Jun 16, 2022 3:28pm
Nanobiotix scales down to close gap between cash runway and data
May 19, 2022 5:51am
Neuron23 snags $100M, new Parkinson's disease candidate
Mar 30, 2022 5:00am
ZS invests in Intelligencia's $12M push to reduce clinical risk
Aug 17, 2021 10:06am
Hummingbird takes flight with $125M Novo-led series C
May 18, 2021 9:25am